FLT3 and acute myeloid leukemia: In this exploratory study, we compared the efficacy of salvage therapy with and without sorafenib in AML patients with FLT3 wild-type relapsing after allo-HSCT, and found that salvage therapy containing sorafenib was superior to that without sorafenib with respect to response rates and survival.